Skip to navigation Skip to content

Clinical Trial: SAR442168

Share

Details
Type of MS: SPMS
Treatment mode of action: To improve immune function
Number of Subjects: 1700
Medication: SAR442168 (Inhibiting B-cell receptor signaling by blocking BTK disease activity)
Location: Washington
Institutions:

Inland Northwest Research
610 S Sherman St. Suite 208
Spokane, WA 99202

Contact Information
Deann Dickinson, ext. 704
509-960-2818
ddickinson@inwresearch.com

Funding:

Sanofi

Description

 A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES)
 

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.